0001103021-22-000017.txt : 20220131
0001103021-22-000017.hdr.sgml : 20220131
20220131175740
ACCESSION NUMBER: 0001103021-22-000017
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220127
FILED AS OF DATE: 20220131
DATE AS OF CHANGE: 20220131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vollins James
CENTRAL INDEX KEY: 0001757833
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 22575743
MAIL ADDRESS:
STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL
STREET 2: 4131 PARK LAKE AVE SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
4
1
wf-form4_164366984558819.xml
FORM 4
X0306
4
2022-01-27
0
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001757833
Vollins James
C/O BIODELIVERY SCIENCES INTL, INC.
4131 PARKLAKE AVE. SUITE 225
RALEIGH
NC
27612
0
1
0
0
See Remarks
Common Stock
2022-01-27
4
M
0
16276
0
A
16276
D
Common Stock
2022-01-31
4
M
0
8303
0
A
24579
D
Common Stock
2022-01-31
4
M
0
3834
0
A
28413
D
Stock Options (right to buy)
3.66
2022-01-27
4
A
0
282055
0
A
2032-01-26
Common Stock
282055.0
282055
D
Restricted Stock Units
0.0
2022-01-27
4
A
0
50546
0
A
2025-01-27
Common Stock
50546.0
50546
D
Restricted Stock Units
0.0
2022-01-27
4
M
0
16276
0
D
2024-01-27
Common Stock
16276.0
32552
D
Restricted Stock Units
0.0
2022-01-29
4
M
0
8303
0
D
2023-01-29
Common Stock
8303.0
8303
D
Restricted Stock Units
0.0
2022-01-31
4
M
0
3834
0
D
2022-01-31
Common Stock
3834.0
0
D
The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.
The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Issuer's 2019 Plan. The remaining RSUs vest on January 29, 2023.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended.
General Counsel, Chief Compliance Officer & Corporate Secretary
/s/ James Vollins
2022-01-31